Introduced
by
To clarify the definition of prohibited “gifts” from drug manufacturers or distributors to medical service providers.
Referred to the Committee on Health Policy
Reported without amendment
With the recommendation that the substitute (H-1) be adopted and that the bill then pass.
Passed in the House 102 to 5 (details)
Referred to the Committee on Health Policy and Human Services
